Trinity Biotech plc
TRIBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Trinity Biotech plc (TRIB) is listed under Medical Devices. The company carries a $5.9M market cap, placing it firmly in the micro-cap category. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Market Cap
$5.9M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-7.09
EPS (TTM)
$-60.00
EPS (Fwd)
$-1.03
ROE
—
ROA
-5.7%
Cash
$5.1M
Total Debt
$138.0M
Free CF
-$11.2M
52W Change
-76.1%
Annual Financials
Cash vs Debt
Where TRIB stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, TRIB finished 58.43% below its 150-day moving average ($14.53) and 64.11% below its 200-day moving average ($16.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRIB overbought or oversold?
At the October 9, 2026 close, TRIB's RSI(14) was 36.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TRIB has $5.1M in cash with $138.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$11.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $62.5M (2022) to $43.8M (2025), a 30% decline worth watching.
Trinity Biotech plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TRIB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.